

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Agger et al.
Appl. No. : 10/563,731
Filed : January 6, 2006
For : ADJUVANT COMBINATIONS
OF LIPOSOMES AND
MYCOBACTERIAL LIPIDS FOR
IMMUNIZATION
COMPOSITIONS AND
VACCINES
Examiner : Nina Archie
Group Art Unit : 1645

CERTIFICATE OF EFS WEB
TRANSMISSION

I hereby certify that this correspondence, and any other attachment noted on the automated Acknowledgement Receipt, is being transmitted from within the Pacific Time zone to the Commissioner for Patents via the EFS Web server on:

February 28, 2008

(Date)


Eric S. Furman Reg. No. 45, 664

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed November 1, 2007, Applicants elect, without traverse, to proceed with examination directed towards Group I, identified by the Examiner as encompassing Claims 1-2, 4, 6-11, and 13-15, drawn to an adjuvant comprising a cationic surfactant and an antigenic component and a delivery system. Pursuant to linking claim practice and for the purpose of examination only, Applicants elect the species DDA, as the surfactant.

Applicants note that Claims 1-11, and 13-15 read on the elected invention. Applicants also reserve the right to rejoin Group II pursuant to the rejoinder doctrine since Claim 12 is directed to a method of making the elected composition.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.